Biomedical Research Institute INCLIVA, Valencia, Spain.
Biomedical Research Institute INCLIVA, Valencia, Spain; Clinical Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.
ESMO Open. 2021 Feb;6(1):100039. doi: 10.1016/j.esmoop.2020.100039. Epub 2021 Jan 18.
Recently, microRNAs have been demonstrated to be potential non-invasive biomarkers for diagnosis, prognosis assessment or prediction of response to treatment in cancer. In this study, we evaluate the potential of miR-30b-5p as a biomarker for early diagnosis of breast cancer (BC) in tissue and plasma.
Expression of miR-30b-5p was determined in a series of 112 BC and 40 normal breast tissues. Circulating miR-30b-5p levels in plasma samples were determined in a discovery cohort of 38 BC patients and 40 healthy donors and in a validation cohort of 83 BC patients and 83 healthy volunteers. miR-30b-5p expression was measured by quantitative real-time PCR and receiver operating characteristics curve analysis was carried out.
The miR-30b-5p expression was significantly lower in BC tissue than in healthy breast samples. In contrast, circulating miR-30b-5p levels were significantly higher in BC patients compared with healthy donors. Furthermore, circulating miR-30b-5p levels were significantly higher in patients with positive axillary lymph node and de novo metastatic patients. Receiver operating characteristics curve analysis demonstrated a good diagnostic potential of miR-30b-5p to detect BC even at an early stage of the disease.
Thus, we highlight the potential of miR-30b-5p as a non-invasive, fast, reproducible and cost-effective diagnostic biomarker of BC.
最近，miRNA 已被证明是癌症诊断、预后评估或治疗反应预测的潜在非侵入性生物标志物。在这项研究中，我们评估了 miR-30b-5p 作为组织和血浆中乳腺癌（BC）早期诊断生物标志物的潜力。
在 112 例 BC 和 40 例正常乳腺组织的系列中测定了 miR-30b-5p 的表达。在 38 例 BC 患者和 40 例健康供体的发现队列以及 83 例 BC 患者和 83 例健康志愿者的验证队列中测定了血浆样本中循环 miR-30b-5p 水平。通过定量实时 PCR 测量 miR-30b-5p 的表达，并进行了接收者操作特征曲线分析。
BC 组织中的 miR-30b-5p 表达明显低于健康乳腺样本。相比之下，BC 患者的循环 miR-30b-5p 水平明显高于健康供体。此外，腋窝淋巴结阳性和新发转移性患者的循环 miR-30b-5p 水平明显更高。接收者操作特征曲线分析表明，miR-30b-5p 具有良好的诊断潜力，即使在疾病的早期阶段也能检测到 BC。
因此，我们强调了 miR-30b-5p 作为一种非侵入性、快速、可重复和具有成本效益的 BC 诊断生物标志物的潜力。
